An extensive safety analysis performed on pooled data from six zanubrutinib monotherapy trials revealed a notable trend toward favorable tolerability among patients diagnosed with various B-cell malignancies[ 29 ].
← all excerpts
Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy.
1
—
—